

What is claimed is:

- 5 1. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
2. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate in crystalline
10 form, having a melting point of $T_{m.p.} = 305 \pm 5^{\circ}\text{C}$ (determined by DSC; evaluation using peak-maximum; heating rate: $10^{\circ}\text{C}/\text{min}$).
3. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate
15 according to claim 2, the X-ray powder diagram of which includes, *inter alia*, the characteristic values $d = 5.43 \text{ \AA}$, 5.08 \AA , 4.71 \AA , 4.50 \AA and 4.43 \AA with an intensity of more than 40%.
4. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate
20 according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions:
 $a = 16.332 \text{ \AA}$,
 $b = 19.199 \text{ \AA}$,
 $c = 11.503 \text{ \AA}$,
25 $\alpha = 95.27^{\circ}$,
 $\beta = 90.13^{\circ}$,
 $\gamma = 110.83^{\circ}$ and
 $V = 3354.4 \text{ \AA}^3$
- 30 5. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate according to one of claims 2 to 4, in the form of the hemihydrate.
6. A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-

methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and one or more inert carriers and/or diluents.

7. A metabolite of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
8. A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
9. A method for treating excessive or abnormal cell proliferation which comprises administering a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.